Literature DB >> 16785063

Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.

Rocío Parody1, Rodrigo Martino, Montserrat Rovira, Lourdes Vazquez, María José Vázquez, Rafael de la Cámara, Cristina Blazquez, Francesc Fernández-Avilés, Enric Carreras, Miguel Salavert, Isidro Jarque, Carmen Martín, Francisco Martínez, Javier López, Antonio Torres, Jorge Sierra, Guilllermo F Sanz.   

Abstract

We evaluated the occurrence of severe infections in 192 consecutive adult recipients of volunteer unrelated donor allogeneic hematopoietic stem cell transplants, with a detailed analysis of severe infections after receipt of cord blood transplants (CBTs; n = 48) or bone marrow transplants (BMTs)/peripheral blood stem cell transplants (PBSCTs; n = 144). At a 3-year median follow-up, CBT recipients had a higher risk of developing any severe infection (85% versus 69% in BMT/PBSCT recipients, P < .01). CBT recipients had a higher incidence of severe bacterial infections before day +100, but at 3 years the risks of these and other infections were similar in the CBT and BMT/PBSCT groups. In addition, the 100-day and 3-year incidences of infection-related mortality (IRM) did not differ between groups (P = .2 and .5, respectively). In multivariate analysis, the most significant risk factor for IRM in all 192 patients was monocytopenia (.2 x 10(9)/L). In CBT recipients, only neutropenia (.2 x 10(9)/L) on day +30 and low nucleated cell dose infusion (< 2 x 10(7)/kg) showed a trend for increased IRM (P = .05 in both cases). Stem cell source had no effect on day +100 or 3-year nonrelapse mortality (NRM), cytomegalovirus infection, cytomegalovirus disease (7% versus 6%), or overall survival (36% versus 39%, respectively). The number of mismatches in HLA (A, B, and DRB1) had no effect on any outcome in CBT recipients. In contrast, in the BMT/PBSCT group, the presence of any mismatch by low or high-resolution HLA typing (A, B, C, and DRB1) increased NRM and decreased overall survival (P < .01). IRM was the primary or secondary cause of death in 61% and 59% of CBT and BMT/PBSCT recipients who died, respectively. Our results confirm the relevance of severe infectious complications as source of severe morbidity and NRM after volunteer unrelated donor hematopoietic stem cell transplantation in adults, but suggest that CBT recipients have a similar risk of dying from an infection if an accurate selection of a cord blood unit is done.

Entities:  

Mesh:

Year:  2006        PMID: 16785063     DOI: 10.1016/j.bbmt.2006.03.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  50 in total

1.  Prophylaxis of invasive fungal diseases in patients with hematologic disorders.

Authors:  Corrado Girmenia
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

Review 2.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

3.  Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.

Authors:  Eun Sang Yi; Yae-Jean Kim
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

4.  Cord colitis syndrome: a cause of granulomatous inflammation in the upper and lower gastrointestinal tract.

Authors:  Nitin K Gupta; Ricard Masia
Journal:  Am J Surg Pathol       Date:  2013-07       Impact factor: 6.394

5.  Late infectious complications after cord blood stem cell transplantation.

Authors:  N G Almyroudis; J Fabian; T Hahn; B H Segal; M Wetzler; P L McCarthy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-12       Impact factor: 3.267

6.  Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients.

Authors:  Filippo Milano; Steven A Pergam; Hu Xie; Wendy M Leisenring; Jonathan A Gutman; Ivy Riffkin; Victor Chow; Michael J Boeckh; Colleen Delaney
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 7.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

8.  Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

Authors:  Suzanne M McGoldrick; Marie E Bleakley; Abraham Guerrero; Cameron J Turtle; Tori N Yamamoto; Shalini E Pereira; Colleen S Delaney; Stanley R Riddell
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

9.  Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Authors:  Sarah Anand; Samantha Thomas; Kelly Corbet; Cristina Gasparetto; Gwynn D Long; Richard Lopez; Ashley K Morris; David A Rizzieri; Keith M Sullivan; Anthony D Sung; Stefanie Sarantopoulos; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-17       Impact factor: 5.742

10.  Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.

Authors:  U Gergis; K Markey; J Greene; M Kharfan-Dabaja; T Field; G Wetzstein; M J Schell; Y Huang; C Anasetti; J Perkins
Journal:  Bone Marrow Transplant       Date:  2009-08-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.